Racial differences in outcomes for patients with metastatic breast cancer by disease subtype

Breast Cancer Research and Treatment

Volumn 151, Issue 3, 2015, Pages 697-707

  Vaz Luis, Ines ^a   Lin, Nancy U ^a   Keating, Nancy L ^b,c   Barry, William T ^a   Lii, Huichuan ^c   Winer, Eric P ^a   Freedman, Rachel A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Disease subtype; Metastatic breast cancer; Racial disparities; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; EIF3A PROTEIN, HUMAN; INITIATION FACTOR 3; TUMOR MARKER;

AGED; ARTICLE; BLACK PERSON; BREAST CANCER; BREAST METASTASIS; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CAUCASIAN; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; EDUCATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MARRIED WOMAN; MEDICARE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; RACE DIFFERENCE; SENSITIVITY ANALYSIS; SINGLE WOMAN; SOCIAL STATUS; SURVIVAL TIME; UNITED STATES; VERY ELDERLY; AGE; BREAST NEOPLASMS; ETHNIC GROUP; HEALTH SURVEY; METASTASIS; MORTALITY; PATHOLOGY; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; ETHNIC GROUPS; EUKARYOTIC INITIATION FACTOR-3; FEMALE; HUMANS; NEOPLASM METASTASIS; PATIENT OUTCOME ASSESSMENT; POPULATION SURVEILLANCE; RISK FACTORS; SEER PROGRAM; UNITED STATES;

EID: 84930149789     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3432-1     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA 61(2):69–90. doi:10.3322/caac.20107
2. Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717
3. Miller KD, Sledge GW Jr (1999) The role of chemotherapy for metastatic breast cancer. Hematol/oncol clin N Am 13(2):415–434
4. Chia SK, Speers CH, D’Yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O’Reilly SE, Olivotto IA (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110(5):973–979. doi:10.1002/cncr.22867
5. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, Delaloge S, Spielmann M (2004) Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 22(16):3302–3308. doi:10.1200/JCO.2004.08.095
6. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104(8):1742–1750. doi:10.1002/cncr.21359
7. Dafni U, Grimani I, Xyrafas A, Eleftheraki AG, Fountzilas G (2010) Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 119(3):621–631. doi:10.1007/s10549-009-0630-8
8. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP (2008) Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 100(24):1780–1791. doi:10.1093/jnci/djn414
9. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN (2004) Is breast cancer survival improving? Cancer 100(1):44–52. doi:10.1002/cncr.11859
10. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH (2008) Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26(30):4891–4898. doi:10.1200/JCO.2007.14.1168
11. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28(1):92–98. doi:10.1200/JCO.2008.19.9844
12. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. doi:10.1056/NEJM200103153441101
13. National Comphreensive Cancer Network Clinical practice guidelines in Oncology (NCCN guidelines). Breast Cancer. Version 3. 2014. http://www.nccn.org
14. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van’t Veer L, Viale G, Krop I, Winer E (2012) 1st international consensus guidelines for advanced breast cancer (ABC 1). Breast (Edinburgh, Scotland) 21(3):242–252. doi:10.1016/j.breast.2012.03.003
15. Cardoso F, Fallowfield L, Costa A, Castiglione M, Senkus E, Group EGW (2011) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi25–vi30. doi:10.1093/annonc/mdr372
16. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clinl Oncol 27(12):1999–2006. doi:10.1200/JCO.2008.19.6618
17. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743. doi:10.1056/NEJMoa064320
18. Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP, American Society of Clinical O (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(19):2078–2099. doi:10.1200/JCO.2013.54.0948
19. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295(21):2492–2502. doi:10.1001/jama.295.21.2492
20. Rugo HS, Brufsky AM, Ulcickas Yood M, Tripathy D, Kaufman PA, Mayer M, Yoo B, Abidoye OO, Yardley DA (2013) Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 141(3):461–470. doi:10.1007/s10549-013-2697-5
21. Silber JH, Rosenbaum PR, Clark AS, Giantonio BJ, Ross RN, Teng Y, Wang M, Niknam BA, Ludwig JM, Wang W, Even-Shoshan O, Fox KR (2013) Characteristics associated with differences in survival among black and white women with breast cancer. JAMA 310(4):389–397. doi:10.1001/jama.2013.8272
22. Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J, Guth AA (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24(9):1357–1362. doi:10.1200/JCO.2005.04.5799
23. Freedman RA, He Y, Winer EP, Keating NL (2009) Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol 27(5):713–719
24. Jatoi I, Anderson WF, Rao SR, Devesa SS (2005) Breast cancer trends among black and white women in the United States. J Clin Oncol 23(31):7836–7841. doi:10.1200/JCO.2004.01.0421
25. Wu XC, Lund MJ, Kimmick GG, Richardson LC, Sabatino SA, Chen VW, Fleming ST, Morris CR, Huang B, Trentham-Dietz A, Lipscomb J (2012) Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 30(2):142–150. doi:10.1200/JCO.2011.36.8399
26. Freedman RA, Hughes ME, Ottesen RA, Weeks JC, He Y, Wong YN, Theriault R, Keating NL (2013) Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer 119(4):839–846. doi:10.1002/cncr.27831
27. Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss H, Norton L, Shapiro C, Bakri K, Marcom K, Lake D, Schwartz JH, Hudis C, Winer EP (2008) Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840–Cancer and Leukemia Group B. J Clin Oncol 26(16):2659–2665
28. Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Borm GF, Tjan-Heijnen VC (2013) Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat 141(3):507–514. doi:10.1007/s10549-013-2711-y
29. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119. doi:10.1056/NEJMoa1113216
30. Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU (2013) Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast (Edinburgh, Scotland) 22(4):525–531. doi:10.1016/j.breast.2012.12.006
31. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30(15):1879–1887. doi:10.1200/JCO.2011.38.2010
32. Ismail-Khan R, Bui MM (2010) A review of triple-negative breast cancer. Cancer Control 17(3):173–176
33. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC (2012) Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118(22):5463–5472. doi:10.1002/cncr.27581
34. Kaufman PA, Brufsky AM, Mayer M, Rugo HS, Tripathy D, Yood MU, Feng S, Wang LI, Quah CS, Yardley DA (2012) Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat 135(3):875–883. doi:10.1007/s10549-012-2209-z
35. Griffiths RI, Lalla D, Herbert RJ, Doan JF, Brammer MG, Danese MD (2011) Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. Cancer Investig 29(9):573–584. doi:10.3109/07357907.2011.616251
36. Schneider M, Zuckerman IH, Onukwugha E, Pandya N, Seal B, Gardner J, Mullins CD (2011) Chemotherapy treatment and survival in older women with estrogen receptor-negative metastatic breast cancer: a population-based analysis. J Am Geriatr Soc 59(4):637–646. doi:10.1111/j.1532-5415.2011.03351.x
37. Potosky AL, Warren JL, Riedel ER, Klabunde CN, Earle CC, Begg CB (2002) Measuring complications of cancer treatment using the SEER-Medicare data. Med Care 40 (8 Suppl): IV-62-68. doi:10.1097/01.MLR.0000020937.94860.99
38. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40 (8 Suppl):IV-3-18. doi:10.1097/01.MLR.0000020942.47004.03
39. Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53(12):1258–1267
40. Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251
41. Mandelblatt JS, Sheppard VB, Neugut AI (2013) Black-white differences in breast cancer outcomes among older Medicare beneficiaries: does systemic treatment matter? JAMA 310(4):376–377. doi:10.1001/jama.2013.8273
42. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106(5):dju055. doi:10.1093/jnci/dju055
43. Hassett MJ, Ritzwoller DP, Taback N, Carroll N, Cronin AM, Ting GV, Schrag D, Warren JL, Hornbrook MC, Weeks JC (2012) Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. doi:10.1097/MLR.0b013e318277eb6f
44. Waldman LT, Bean W, Levine AL, Cohen-Bearak A, Phelps FA, Svoboda L, Freedman R, Elfiky A, Berlin S, Abel GA, Deutsch C, Lathan CS (2013) Using fasttrack to implement an Academic Medical Center and Community Health Center collaborative for cancer care delivery. Healthcare 1(3–4):130–135. doi:10.1016/j.hjdsi.2013.09.002